| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Bolt Biotherapeutics, Inc.
13D/A
BOLT · 097702203
|
4.6% |
2/26/2026
Event 2/24/2026
|
||||
| Nan Fung Group Holdings Limited | 4.6% | |||||
| NF Investment Holdings Limited | 4.6% | |||||
| Pivotal bioVenture Partners Fund I, L.P. | 2.7% | |||||
| Pivotal bioVenture Partners Fund I G.P., L.P. | 2.7% | |||||
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 2.7% | |||||
| Pivotal Partners Ltd | 2.7% | |||||
| Pivotal Life Sciences Holdings Limited | 2.7% | |||||
| Nan Fung Life Sciences Holdings Limited | 4.3% | |||||
| Permwell Management Limited | 0.3% | |||||
| NFLS Beta Limited | 1.6% | |||||
| NFLS Platform Holdings Limited | 1.6% | |||||
|
Inozyme Pharma, Inc.
13D/A
INZY · 45790W108
|
0% |
8/27/2025
Event 7/1/2025
|
||||
| Pivotal bioVenture Partners Fund I, L.P. | 0% | |||||
| Pivotal bioVenture Partners Fund II, L.P. | 0% | |||||
| Pivotal bioVenture Partners Fund II G.P. Ltd | 0% | |||||
| Pivotal bioVenture Partners Fund I G.P., L.P. | 0% | |||||
| Pivotal bioVenture Partners Fund I U.G.P. Ltd | 0% | |||||
| Pivotal Partners Ltd | 0% | |||||
| Pivotal Life Sciences Holdings Limited | 0% | |||||
| Nan Fung Life Sciences Holdings Limited | 0% | |||||
| NF Investment Holdings Limited | 0% | |||||
| Nan Fung Group Holdings Limited | 0% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Evommune, Inc.
13G
EVMN · 30054Y107
|
10.9% |
2/13/2026
Event 12/31/2025
|
||||
| Nan Fung Group Holdings Limited | 10.9% | |||||
| NF Investment Holdings Limited | 10.7% | |||||
| Nan Fung Life Sciences Holdings Limited | 10.7% | |||||
| NFLS Platform Holdings Limited | 4.6% | |||||
| NFLS Delta III Limited | 4.6% | |||||
| Pivotal Life Sciences Holdings Limited | 6.1% | |||||
| Pivotal Partners Ltd | 6.1% | |||||
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 5.2% | |||||
| Pivotal bioVenture Partners Fund I G.P., L.P. | 5.2% | |||||
| Pivotal bioVenture Partners Fund I, L.P. | 5.2% | |||||
| Pivotal bioVenture Partners Fund II G.P. Ltd | 0.9% | |||||
| Pivotal bioVenture Partners Fund II, L.P. | 0.9% | |||||
| NFLS Delta Limited | 4.6% | |||||
|
Oculis Holding AG
13G/A
OCS · H5870P102
|
4.9% |
11/14/2025
Event 9/30/2025
|
||||
| Nan Fung Group Holdings Limited | 4.9% | |||||
| NF Investment Holdings Limited | 4.9% | |||||
| Nan Fung Life Sciences Holdings Limited | 4.9% | |||||
| NFLS Platform Holdings Limited | 0.9% | |||||
| NFLS Beta Limited | 0.9% | |||||
| Pivotal Life Sciences Holdings Limited | 4.0% | |||||
| Pivotal Partners Ltd | 4.0% | |||||
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 4.0% | |||||
| Pivotal bioVenture Partners Fund I G.P., L.P. | 4.0% | |||||
| Pivotal bioVenture Partners Fund I, L.P. | 4.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.